[1] Yao K, Yang Y. Streptococcus pneumoniae diseases in Chinese children: Past, present and future. Vaccine, 2008; 26, 4425-33. doi:  10.1016/j.vaccine.2008.06.052
[2] Song JH, Jung SI, Ko KS. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia. Antimicrob Agents Chemother, 2004; 48, 2101-7. doi:  10.1128/AAC.48.6.2101-2107.2004
[3] Macheboeuf P, Di Guilmi AM, Job V, et al. Active site restructuring regulates ligand recognition in class A penicillin-binding proteins. Proc Natl Acad Sci, 2005; 102, 577-82. doi:  10.1073/pnas.0407186102
[4] Zerfass I, Hakenbeck R, Denapaite D. An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. Antimicrob Agents Chemother, 2009; 53, 1107-15. doi:  10.1128/AAC.01107-08
[5] Chesnel L, Carapito R, Croizé J, et al. Identical penicillin-binding domains in penicillin-binding proteins of Streptococcus pneumoniae clinical isolates with different levels of beta-lactam resistance. Antimicrob Agents Chemother, 2005; 49, 2895-902. doi:  10.1128/AAC.49.7.2895-2902.2005
[6] Breakpoints C. CLSI Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. CLSI document M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute, 2011.
[7] Huang S, Liu X, Lao W, et al. Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolates collected at a Chinese hospital from 2011 to 2013. BMC Infect Dis, 2015; 15, 312-22. doi:  10.1186/s12879-015-1042-5
[8] Yang F, Xu XG, Yang MJ, et al. Antimicrobial susceptibility and molecular epidemiology of Streptococcus pneumoniae isolated from Shanghai, China. Int J Antimicrob Agents, 2008; 32, 386-91. doi:  10.1016/j.ijantimicag.2008.05.004
[9] Su LH, Wu TL, Kuo AJ, et al. Antimicrobial susceptibility of Streptococcus pneumoniae at a university hospital in Taiwan, 2000-2007: impact of modified non-meningeal penicillin breakpoints in CLSI M100-S18. J Antimicrob Chemother, 2009; 64, 336-42. doi:  10.1093/jac/dkp209
[10] Hackel M, Lascols C, Bouchillon Set, et al. Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations. Vaccine, 2013; 31, 4881-7. doi:  10.1016/j.vaccine.2013.07.054
[11] Davie TA, Shang W, Bush K, et al. Activity of doripenem and comparator β-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x. J Antimicrob Chemother, 2008; 61, 751-3. doi:  10.1093/jac/dkn004
[12] Engel H, Mika M, Denapaite D, et al. A low-affinity penicillin-binding protein 2x variant is required for heteroresistance in Streptococcus pneumoniae. Antimicrob Agents Chemother, 2014; 58, 3934-41. doi:  10.1128/AAC.02547-14